Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has been used increasingly as an anticoagulant during continuous renal replacement therapy (CRRT). However, there, are limited data from randomized studies on NM use in patients with a bleeding tendency. This prospective study evaluate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Medicine (Baltimore)
Main Authors: Choi, Ji-Young, Kang, Yun-Jeong, Jang, Hye Min, Jung, Hee-Yeon, Cho, Jang-Hee, Park, Sun-Hee, Kim, Yong-Lim, Kim, Chan-Duck
Formato: Artigo
Idioma:Inglês
Publicado: Wolters Kluwer Health 2015
Assuntos:
5200
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5291631/
https://ncbi.nlm.nih.gov/pubmed/26717390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000002392
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares